Effects of controlled diet and prebiotics on the microbiome

ISRCTN ISRCTN53935058
DOI https://doi.org/10.1186/ISRCTN53935058
Secondary identifying numbers 123456
Submission date
02/02/2018
Registration date
23/02/2018
Last edited
12/12/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
There is increasing interest in studying the relationship between disease and the microbial communities inhabiting the human gut. However, relatively little is known about the impact of dietary patterns and other environmental influences on gut microbial composition, making identification of disease-specific microbial signatures in patient populations with a variable diet problematic. In particular, it has been observed in both mice and humans that the composition of fecal microbiota differs in obese versus lean individuals, prompting the hope that interventions targeting the gut microbiota may offer a viable complementary strategy for combating obesity moving forward. However, it remains to be shown that these differences are not directly attributable to the dietary habits of the individuals in question. Indeed, previous studies in humans have contrasted the effects of certain types of dietary interventions (e.g. plant-based versus animal-based diets) on the gut microbiome, giving us a coarse-grained appreciation of the microbial patterns associated with diet. This study aims to probe the specifics of diet-related microbial signatures by observing the effect of different dietary supplements on the gut microbiota of health individuals. The effect of introducing particular dietary supplements, such as specific types of dietary fibers or omega-3 fats, will be compared between these two populations, and further examine whether diet-related changes can explain the differences between their microbial compositions. In addition, the information can be used to correct for strong correlations between diet and the microbiome in analyses aiming to identify gut microbial signatures involved in a variety of human diseases.

Who can participate?
Adults aged 18-70 who have a BMI between 18-25 or above 30.

What does the study involve?
Participants provide stool samples on two consecutive days as baseline, during which participants consume their ordinary diet, as desired. In the evening of the second day, participants perform a bowel cleanse with PEG, and the following morning begin a period of six days during which their diet is fixed. The diet of the first three days are common to all participants, and consists of water and a nutritional meal replacement (Ensure) ad libitum. This is then followed by a further three days during which participants consume the nutritional meal replacement in addition to a specific micronutrient supplement to which they were randomized at the beginning of the study. Supplements considered include inulin, pectin, cellulose, fish oil, coconut oil and protein powder. Participants are then instructed to resume their normal diet after day 6, and follow up samples are collected one day and one week after resuming their ordinary diet. Stool samples are collected daily (or, failing that, as often as possible), and processed for 16S rRNA and metagenomics sequencing to assess the effect on the composition of the microbiota.

What are the possible benefits and risks of participating?
There are no anticipated benefits or risks to participants of the study.

Where is the study run from?
Massachusetts Institute of Technology (USA)

When is the study starting and how long is it expected to run for?
June 2015 to December 2017

Who is funding the study?
MIT Center for Microbiome Informatics and Therapeutics (USA)

Who is the main contact?
Professor Eric Alm (Public)
Dr Thomas Gurry (Scientific)

Contact information

Prof Eric Alm
Public

MIT Center for Microbiome Informatics and Therapeutics
500 Technology Square
Cambridge
02139
United States of America

ORCiD logoORCID ID 0000-0001-8294-9364
Dr Thomas Gurry
Scientific

MIT Center for Microbiome Informatics and Therapeutics
500 Technology Square
Cambridge
02139
United States of America

Study information

Study designInterventional non randomised study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Other
Study typeOther
Participant information sheet No participant information sheet available
Scientific titlePredictability and persistence of prebiotic dietary supplementation in a healthy human cohort
Study hypothesisThe study is based on the hypothesis that controlling dietary background will allow for higher resolution in our ability to discern individual bacterial species that respond to prebiotics.
Ethics approval(s)MIT Committee on the Use of Humans as Experimental Subjects, 29/06/2015, ref#: 1504007066.
ConditionDiet and the microbiome
InterventionThis study aims to identify the microbial responders to specific micronutrients in the human diet. By placing a cohort of approximately 50 healthy human individuals on a diet consisting entirely of a nutritional meal replacement milkshake and water, and controlling for dietary background, and against this background, supplement the participants' diet with individual micronutrients. Stool samples are collected and the bacterial DNA in them are sequenced to quantify the bacterial communities and the abundances of specific bacteria in each sample. In this manner, we are able to measure the effect of specific prebiotic supplements on the composition of the human gut microbiome.

Participants are placed on a diet consisting entirely of a liquid nutritional meal replacement for three days, and then for three further days in addition to a prebiotic spike-in of choice; microbiome composition is measured throughout the course of the intervention.

The study involves comparing the effects of a controlled diet in contrast to a variable diet on the composition of the gut microbiota. The methodology involves obtaining stool samples on two consecutive days as baseline, during which participants consume their ordinary diet, as desired. In the evening of the second day, participants perform a bowel cleanse with PEG, and the following morning begin a period of six days during which their diet is fixed. The composition of the diet on the first three days are common to all participants, and consists of water and a nutritional meal replacement (Ensure) ad libitum. This is then followed by a further three days during which participants consume the nutritional meal replacement in addition to a specific micronutrient supplement to which they were randomized at the beginning of the study. Supplements considered include inulin, pectin, cellulose, fish oil, coconut oil and protein powder. Participants are then instructed to resume their normal diet after day 6, and follow up samples are collected one day and one week after resuming their ordinary diet. Stool samples are collected daily (or, failing that, as often as possible), and processed for 16S rRNA and metagenomics sequencing to assess the effect on the composition of the microbiota.
Intervention typeSupplement
Primary outcome measureGut microbiota composition is measured using the stool samples collected on the two first baseline days and on each day during the provided dietary regimen. This consists of a maximum of 10 stool samples (two baseline, six intervention, and two follow-up), which are sequenced for the 16S rRNA gene.
Secondary outcome measuresThe effect of the diet on the microbiota at the level of genes and bacterial strains are processed for metagenomics sequencing at the second baseline sample, day 3 sample, and day 6 sample.
Overall study start date29/06/2015
Overall study end date31/12/2017

Eligibility

Participant type(s)Healthy volunteer
Age groupAdult
Lower age limit18 Years
Upper age limit70 Years
SexBoth
Target number of participants75
Participant inclusion criteria1. Individuals between 18-70 years of age
2. BMI between 18-25 or above 30
3. A waist-to-hip ratio of more than 0.9
Participant exclusion criteria1. Food allergies
2. Inability to comply with study procedure
3. Suffer from IBS, IBD, Type-2 diabetes, kidney disease or intestinal obstruction
4. Allergic to polyethylene glycol
5. Have received antibiotics in the last 6 months
6. Have untreated, in situ colorectal cancer
7. Are currently pregnant, planning to get pregnant in the next 60 days, or currently breastfeeding
Recruitment start date01/07/2015
Recruitment end date01/12/2017

Locations

Countries of recruitment

  • United States of America

Study participating centre

Massachusetts Institute of Technology
500 Technology Square
Cambridge
02139
United States of America

Sponsor information

MIT Center for Microbiome Informatics and Therapeutics
Research organisation

500 Technology Square
Cambridge
02139
United States of America

Website microbiome.mit.edu
ROR logo "ROR" https://ror.org/042nb2s44

Funders

Funder type

University/education

MIT Center for Microbiome Informatics and Therapeutics

No information available

Results and Publications

Intention to publish date01/06/2018
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planWe are currently undergoing peer-review and anticipate publication in a peer reviewed journal in early to mid-2018. No additional documents are available.
IPD sharing planThe datasets generated (16S and shotgun metagenomics) during and/or analysed during the current study are/will be available upon request from the corresponding author, Prof. Eric Alm. Only deidentified data will be shared.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 23/08/2018 Yes No

Editorial Notes

12/12/2018: Publication reference and IPD sharing statement added.